PharmacoEconomics - Open

2017 - 2025

Current editor(s): Timothy Wrightson and Christopher Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 8, issue 6, 2024

Modernizing Newborn Screening in the Genomic Era: Importance of Health-Related Quality of Life pp. 787-792

Ellen Kim DeLuca, Ann Chen Wu, Kurt D. Christensen, Davene R. Wright, Jennifer Yeh and Hadley Stevens Smith

A Systematic Review of the Impact of Spinal Cord Injury on Costs and Health-Related Quality of Life pp. 793-808

Modou Diop and David Epstein

Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore pp. 809-822

Clarence Ong, Jamaica Briones, Zhi Zhen Lim, Nisha Suyien Chandran, Haur Yueh Lee, Benny Kaihui Li, Yik Weng Yew and Hwee-Lin Wee

Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses pp. 823-836

Fatemeh Mirzayeh Fashami, Jean-Eric Tarride, Behnam Sadeghirad, Kimia Hariri, Amirreza Peyrovinasab and Mitchell Levine

Economic Impact of Bladder Cancer in the USA pp. 837-845

Otavio Clark, Tulio Sarmento, Anthony Eccleston, Julia Brinkmann, Renato Picoli, Vamsi Daliparthi, Jorine Voss, Sanjana Chandrasekar, Allison Thompson and Jane Chang

Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study pp. 847-856

Matilde Slot, Thomas Bøjer Rasmussen, Mette Nørgaard, Carsten Schade Larsen and Lars Holger Ehlers

Clinicians’ Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment pp. 857-867

Alexander Keenan, Chiara Whichello, Hoa H. Le, David M. Kern, Gabriela S. Fernandez, Vicky Turner, Anup Das, Matt Quaife and Amy Perrin Ross

Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico pp. 869-885

Denisse Añorve Bailon, Javier Picó-Guzmán, Sergio Cifuentes, Rogelio Trejo, Jeronimo Rodríguez Cid, Juan Jose Juarez-Vignon Whaley, Alan Alexis Heredia Zepeda, Raquel Gerson, Christian Patricio Camacho-Limas, José Fabián Martínez-Herrera, Diana Bonilla Molina, Efraín Camarín Sánchez and Daniela Shveid Gerson

Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain pp. 887-896

Sergio Cedillo, Almudena González-Domínguez, Yoana Ivanova-Markova, Rafael López López, Sara López-Tarruella Cobo and José Alberto Peña Pedrosa

Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians pp. 897-909

Marion Tano, Pascal Paubel, Matthieu Ribault and Albane Degrassat-Théas

Estimating Australian Population Utilities for Inherited Retinal Disease Using Time Trade-Off pp. 911-922

Maria Farris, Stephen Goodall, Richard Abreu Lourenco, Brendan Mulhern, Kathleen Manipis, Elena Meshcheriakova and Milena Lewandowska

Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK pp. 923-934

Danny Gibson, Neil Branscombe, Neil Martin, Andrew Menzies-Gow, Priya Jain, Katherine Padgett and Florian Yeates

The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System pp. 935-943

Sam Harper, Muralikrishnan Kartha, Stuart Mealing, Maurizio Pavanello and Luigi Bonavina

Artificial-Intelligence Cloud-Based Platform to Support Shared Decision-Making in the Locoregional Treatment of Breast Cancer: Protocol for a Multidimensional Evaluation Embedded in the CINDERELLA Clinical Trial pp. 945-959

Ludovica Borsoi, Elisabetta Listorti and Oriana Ciani

Correction: Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore pp. 961-961

Clarence Ong, Jamaica Briones, Zhi Zhen Lim, Nisha Suyien Chandran, Haur Yueh Lee, Benny Kaihui Li, Yik Weng Yew and Hwee-Lin Wee

Publisher Correction: Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison Between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses pp. 963-965

Fatemeh Mirzayeh Fashami, Jean-Eric Tarride, Behnam Sadeghirad, Kimia Hariri, Amirreza Peyrovinasab and Mitchell Levine

Volume 8, issue 5, 2024

NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances pp. 645-649

Dawn Lee, Darren Burns and Ed Wilson

Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers pp. 651-664

Diana Beatriz Bayani, Yihao Clement Lin, Chandramouli Nagarajan, Melissa G. Ooi, Allison Ching Yee Tso, John Cairns and Hwee Lin Wee

Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment pp. 665-678

Jürgen Wasem, Yanic Heer, Eleni Karamasioti, Erwan Muros-Le Rouzic, Giuseppe Marcelli, Danilo Maio, Stefan Braune, Gisela Kobelt and Paul Dillon

Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story pp. 679-688

She Hui Tan, Louise Gek Huang Goh, Benjamin Shao Kiat Ong, Darren Sze Guan Ng, Liang Lin, Raymond Chee Hui Ng, Bernard Yu-Hor Thong and Kwong Ng

A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France pp. 689-699

Paul Casabianca, Marc Massetti, François-Emery Cotte, Romain Moreau, Sarah Kassahun, Prianka Singh, Inkyu Kim, Anne-Françoise Gaudin, Guillaume Piessen and Henri Leleu

Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy pp. 701-714

Jonathan Salcedo, Daniel Hill-McManus, Chloë Hardern, Oyin Opeifa, Raffaella Viti, Ludovica Siviero, Antonio Saverio Roscini and Gennaro Martino

Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata pp. 715-725

Andrew Lloyd, Daniel Aggio, Caleb Dixon, Ernest H. Law and Thomas Price

Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina pp. 727-738

Natalia Espinola, Constanza Silvestrini, Carla Colaci, Daniela Sugg, Carlos Rojas-Roque, Jesica Coelli and Federico Augustovski

A Cost Evaluation of COVID-19 Remote Home Monitoring Services in England pp. 739-753

Sonila M. Tomini, Efthalia Massou, Nadia E. Crellin, Naomi J. Fulop, Theo Georghiou, Lauren Herlitz, Ian Litchfield, Pei Li Ng, Chris Sherlaw-Johnson, Manbinder S. Sidhu, Holly Walton and Stephen Morris

ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation pp. 755-764

Richard Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan and Nicholas Adlard

Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review pp. 765-772

Vittoria Ardito, Ludovico Cavallaro, Michael Drummond and Oriana Ciani

Using a Patient-Centered Multicriteria Decision Analysis to Assess the Value of Multiple Sclerosis Treatments in the US: A Study Protocol pp. 773-781

Surachat Ngorsuraches, Tim C. Lai, Rebecca Habermann, Yolanda Wheeler and William Meador

Correction: NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances pp. 783-783

Dawn Lee, Darren Burns and Ed Wilson

Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older pp. 785-785

Sydney George, Justin Carrico, Katherine A. Hicks, Dessi Loukov, Cheryl Ng, Jessica Regan and Nikolaos Giannelos

Volume 8, issue 4, 2024

Whither Decision-Analytic Modelling-Based Economic Evaluation for Health Care Decision Making? pp. 507-510

Rachael Maree Hunter and Matthew Franklin

A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab pp. 511-524

Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Lisa Aniek Jong, Didik Setiawan and Maarten Jacobus Postma

Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension pp. 525-537

Rod S. Taylor, Anthony Bentley, Kaylie Metcalfe, Melvin D. Lobo, Ajay J. Kirtane, Michel Azizi, Christopher Clark, Kieran Murphy, Jennifer H. Boer, Marjolijn Keep, An Thu Ta, Neil C. Barman, Garrett Schwab, Ron Akehurst and Roland E. Schmieder

Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France pp. 539-557

Gérard Pouvourville, Manon Breau-Brunel, Véronique Loncle-Provot, Ekkehard Beck, Loïg Gaugain, Gaëlle Nachbaur and Céline Pribil

Public Preference for Financing Preventive Vaccines in Health Shocks: The Case of COVID-19 Vaccines in a Middle-Income Country pp. 559-568

Najmeh Moradi, Leila Zarei, Narges Hajimoladarvish, Zahra Meshkani, Marzieh Zanganeh, Jafar Babapour and Kamran Bagheri Lankarani

Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model pp. 569-583

Emma McManus

Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina pp. 585-598

Carlos Rojas-Roque, Constanza Silvestrini, Fernando Argento, Daniela Sugg, Federico Augustovski, Jesica Coelli and Natalia Espinola

Cost of Care for Non-communicable Diseases: Which Types of Healthcare Providers are the Most Economical in India’s Chhattisgarh State? pp. 599-609

Samir Garg, Narayan Tripathi and Kirtti Kumar Bebarta

A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales pp. 611-626

Colin Burke, Catriona Crossan, Emma Tyas, Matthew Hemstock, Dawn Lee and Sally Bowditch

Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients—Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs pp. 627-640

Micha J. Pilz, Simone Seyringer, Imad Al-Naesan, Madeleine T. King, Andrew Bottomley, Richard Norman, Lisa Schlosser, Tobias Hell and Eva Maria Gamper

Correction: Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension pp. 641-641

Rod S. Taylor, Anthony Bentley, Kaylie Metcalfe, Melvin D. Lobo, Ajay J. Kirtane, Michel Azizi, Christopher Clark, Kieran Murphy, Jennifer H. Boer, Marjolijn Keep, An Thu Ta, Neil C. Barman, Garrett Schwab, Ron Akehurst and Roland E. Schmieder

Correction: Developing a Natural History Model for Duchenne Muscular Dystrophy pp. 643-643

Jonathan Broomfield, M. Hill, F. Chandler, M. J. Crowther, J. Godfrey, M. Guglieri, J. Hastie, J. Larkindale, J. Mumby-Croft, E. Reuben, F. Woodcock and K. R. Abrams

Volume 8, issue 3, 2024

Introducing Open Science in Teaching Health Economic Modelling pp. 347-357

Xavier G. L. V. Pouwels and Hendrik Koffijberg

Cost-Effectiveness of Routine Monitoring of Long-Term Conditions in Primary Care: Informing Decision Modelling with a Systematic Review in Hypertension, Type 2 Diabetes and Chronic Kidney Disease pp. 359-371

Syed G. Mohiuddin, Mary E. Ward, William Hollingworth, Jessica C. Watson, Penny F. Whiting and Howard H. Z. Thom

Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany pp. 373-387

Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher and Matthias Schwenkglenks

Behind the Scenes: A Qualitative Investigation of Interviewers' Performance in EQ-5D Valuation Studies pp. 389-401

Carlotta Varriale, Giovanni Andrulli, Michela Meregaglia, Fanni Rencz and Aureliano Paolo Finch

Cost-Effectiveness Analysis of Digital Breast Tomosynthesis Added to Synthetic Mammography in Breast Cancer Screening in Brazil pp. 403-416

Henrique Lima Couto, Ludmila Peres Gargano, Vilmar Marques Oliveira, Bertha Andrade Coelho, Eduardo Carvalho Pessoa, Augusto Tufi Hassan, Agnaldo Lopes Silva, Linei Augusta Brolini Delle Urban, Luciano Chala Fernandes, Nisha Sharma, Ritse Mann, Stuart A McIntosh and Fernando Zanghelini

An Economic Evaluation of a Streamlined Day-Case Atrial Fibrillation Ablation Protocol and Conventional Cryoballoon Ablation versus Antiarrhythmic Drugs in a UK Paroxysmal Atrial Fibrillation Population pp. 417-429

Joe W. E. Moss, Derick Todd, Lukasz Grodzicki, Beatrice Palazzolo, Richard Mattock, Stuart Mealing, Maxim Souter, Benedict Brown, Tom Bromilow, Damian Lewis, James McCready, Muzahir Tayebjee, Ewen Shepherd, Thiagarajah Sasikaran, Clare Coyle, Eleni Ismyrloglou, Nicholas A. Johnson and Prapa Kanagaratnam

Identification and prioritisation of items for a draft participant-reported questionnaire to measure use of social care, informal care, aids and adaptations pp. 431-443

Kirsty M. Garfield, Gail A. Thornton, Samantha Husbands, Ailsa Cameron, William Hollingworth, Sian M. Noble, Paul Roy and Joanna C. Thorn

Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis pp. 445-457

Christian Bührer, Thomas Paling, Richard Gale, Tatiana Paulo and Marloes Bagijn

Health-Related Quality of Life and Economic Burden Among Hospitalized Children with Hand, Foot, and Mouth Disease: A Multiregional Study in China pp. 459-469

Ting Zhou, Hongfei Hu, Junyang Gao, Hongjie Yu, Mark Jit and Pei Wang

Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus pp. 471-480

Olga Pitsillidou, Panagiotis Petrou and M. J. Postma

Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older pp. 481-492

Sydney George, Justin Carrico, Katherine A. Hicks, Dessi Loukov, Cheryl Ng, Jessica Regan and Nikolaos Giannelos

A Canadian Simulation Model for Major Depressive Disorder: Study Protocol pp. 493-505

Shahzad Ghanbarian, Gavin W. K. Wong, Mary Bunka, Louisa Edwards, Sonya Cressman, Tania Conte, Sandra Peterson, Rohit Vijh, Morgan Price, Christian Schuetz, David Erickson, Linda Riches, Ginny Landry, Kim McGrail, Jehannine Austin and Stirling Bryan

Volume 8, issue 2, 2024

Health Economic Evaluations of Hemochromatosis Screening and Treatment: A Systematic Review pp. 147-170

Malvina Hoxha, Visar Malaj and Bruno Zappacosta

A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma pp. 171-190

Fei Fei Liu, Meaghan Bartlett and Samantha Craigie

Artificial Intelligence to Automate Health Economic Modelling: A Case Study to Evaluate the Potential Application of Large Language Models pp. 191-203

Tim Reason, William Rawlinson, Julia Langham, Andy Gimblett, Bill Malcolm and Sven Klijn

Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models pp. 205-220

Tim Reason, Emma Benbow, Julia Langham, Andy Gimblett, Sven L. Klijn and Bill Malcolm

The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals pp. 221-233

Jose Luis Calleja, Jaime Espin, Ankita Kaushik, Manuel Hernandez-Guerra, Rob Blissett, Alon Yehoshua and Adam Igloi-Nagy

Cost-Utility Analysis of Total Ankle Replacement Compared with Ankle Arthrodesis for Patients Aged 50–85 Years with End-Stage Ankle Osteoarthritis: The TARVA Study pp. 235-249

Andrew J. Goldberg, Ekaterina Bordea, Kashfia Chowdhury, Iva Hauptmannova, James Blackstone, Deirdre Brooking, Elizabeth L. Deane, Stephen Bendall, Andrew Bing, Chris Blundell, Sunil Dhar, Andrew Molloy, Steve Milner, Mike Karski, Steve Hepple, Malik Siddique, David T. Loveday, Viren Mishra, Paul Cooke, Paul Halliwell, David Townshend, Simon S. Skene and Caroline J. Doré

From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy pp. 251-261

Elvio Emanuele Rossini, Carlotta Galeone, Chiara Lucchetti and Claudio Jommi

Health State Utilities Associated with False-Positive Cancer Screening Results pp. 263-276

Louis S. Matza, Timothy A. Howell, Eric T. Fung, Sam M. Janes, Michael Seiden, Allan Hackshaw, Lincoln Nadauld, Hayley Karn and Karen C. Chung

Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden pp. 277-289

Maria Polyzoi, Mattias Ekman, Anja Reithmeier, Johanna Jacob, Emma Karlsson, Evelina Bertranou, Barbro Linderholm and Robert Hettle

Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain pp. 291-302

Rosa María Romero Jiménez, Pedro Herranz Pinto, Minia Campos Domínguez, Susana Aceituno Mata, Alba Bellmunt, Miriam Prades, Daniel Arumi, Irene Hernández-Martín, Valeria Herrera-Lasso, Noelia Llevat, Alfonso Lossada Juste and Francisco José Rebollo Laserna

An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund pp. 303-311

Laura A. Trigg, Maxwell S. Barnish, Samuel Hayward, Naomi Shaw, Louise Crathorne, Brad Groves, John Spoors, Thomas Strong, G. J. Melendez-Torres and Caroline Farmer

Economic Evaluation of a Personalized Nutrition Plan Based on Omic Sciences Versus a General Nutrition Plan in Adults with Overweight and Obesity: A Modeling Study Based on Trial Data in Denmark pp. 313-331

Milanne Maria Johanna Galekop, Carin Uyl- de Groot and William Ken Redekop

Understanding the Natural History of Chronic Hepatitis D: Proposal of a Model for Cost-Effectiveness Studies pp. 333-343

Ankita Kaushik, Geoffrey Dusheiko, Chong Kim, Nathaniel J. Smith, Csilla Kinyik-Merena, Gian Luca Tanna and Robert J. Wong

Correction: From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy pp. 345-345

Elvio Emanuele Rossini, Carlotta Galeone, Chiara Lucchetti and Claudio Jommi

Volume 8, issue 1, 2024

The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain pp. 5-18

Bérengère Macabeo, Théophile Rotrou, Aurélie Millier, Clément François and Philippe Laramée

Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial pp. 19-30

Laurent Fauchier, Nicolas Lamblin, Jean Tardu, Lucile Bellier, Harinala Groyer, Deborah Ittah, Julien Chollet, Stephan Linden and Pierre Levy

Specialist Palliative Care and Health Care Costs at the End of Life pp. 31-47

Patricia Kenny, Dan Liu, Denzil Fiebig, Jane Hall, Jared Millican, Sanchia Aranda, Kees Gool and Philip Haywood

United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument pp. 49-63

Madeleine T. King, D. A. Revicki, R. Norman, F. Müller, R.C. Viney, A. S. Pickard, D. Cella and J. W. Shaw

Preferences for Living Arrangements in Dementia: A Discrete Choice Experiment pp. 65-78

Christian Speckemeier, Carina Abels, Klemens Höfer, Anja Niemann, Jürgen Wasem, Anke Walendzik and Silke Neusser

Developing a Natural History Model for Duchenne Muscular Dystrophy pp. 79-89

Jonathan Broomfield, M. Hill, F. Chandler, M. J. Crowther, J. Godfrey, M. Guglieri, J. Hastie, J. Larkindale, J. Mumby-Croft, E. Reuben, F. Woodcock and K. R. Abrams

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland pp. 91-101

Andrea Favre-Bulle, Min Huang, Amin Haiderali and Arjun Bhadhuri

Cost of Patients with Alzheimer’s Disease in Spain According to Disease Severity pp. 103-114

Laura Gómez Maldonado, Ricardo de Mora-Figueroa, Angélica López-Angarita, Paulina Maravilla-Herrera and María Merino

Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates pp. 115-118

Jeremy Costin, Morgane C. Mouslim, Mariana P. Socal and Antonio Trujillo

Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis pp. 119-131

Joost G. E. Verbeek, Karen Sluis, Marieke A. Vollebergh, Johanna W. Sandick, Wim H. Harten and Valesca P. Retèl

Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH) pp. 133-146

Hilary M. DuBrock, Hayley D. Germack, Marjolaine Gauthier-Loiselle, Jörg Linder, Ambika Satija, Ameur M. Manceur, Martin Cloutier, Patrick Lefebvre, Sumeet Panjabi and Robert P. Frantz